PI
-
Dose selection of novel anticancer drugs: exposing the gap between selected and required doses
Hoog, C. J. P. O. ., Mehra, N., Maliepaard, M., Bol, K., Gelderblom, H., Sonke, G. S., de Langen, A. J., van de Donk, N. W. C. J., Janssen, J. J. W. M., Minnema, M. C., van Erp, N. P. & Boerrigter, E., 1 Aug 2024, In: The Lancet Oncology. 25, 8, p. e340-e351Research output: Contribution to journal › Review article › Academic › peer-review
-
Health-related quality of life and symptoms of chronic myeloid leukemia patients after discontinuation of tyrosine kinase inhibitors: results from the EURO-SKI Trial
Efficace, F., Mahon, F-X., Richter, J., Piciocchi, A., Cipriani, M., Nicolini, F. E., Mayer, J., Zackova, D., Janssen, J. J. W. M., Panayiotidis, P., Vestergaard, H., Koskenvesa, P., Almeida, A., Hjorth-Hansen, H., Martinez-Lopez, J., Olsson-Strömberg, U., Hochhaus, A., Berger, M. G., Etienne, G., Klamova, H., & 4 others, 1 Aug 2024, In: Leukemia. 38, 8, p. 1722-1730 9 p.Research output: Contribution to journal › Article › Academic › peer-review
-
Correction to: Treatment-free remission after a second TKI discontinuation attempt in patients with Chronic Myeloid Leukemia re-treated with dasatinib – interim results from the DAstop2 trial (Leukemia, (2024), 38, 4, (781-787), 10.1038/s41375-024-02145-6)
Flygt, H., Söderlund, S., Richter, J., Saussele, S., Koskenvesa, P., Stenke, L., Mustjoki, S., Dimitrijevic, A., Stentoft, J., Majeed, W., Roy, L., Wolf, D., Dreimane, A., Gjertsen, B. T., Gedde-Dahl, T., Ahlstrand, E., Markevärn, B., Hjorth-Hansen, H., Janssen, J. & Olsson-Strömberg, U., Apr 2024, In: Leukemia. 38, 4, p. 925 1 p.Research output: Contribution to journal › Comment/Letter to the editor › Academic
- All publications